Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-871-0761
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10,000.00
Profitability
Miscellaneous
Employees21
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions
What is Catalyst Biosciences' stock symbol?
Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."
When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?
Catalyst Biosciences's stock reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.
How were Catalyst Biosciences' earnings last quarter?
Catalyst Biosciences Inc (NASDAQ:CBIO) posted its quarterly earnings data on Thursday, August, 1st. The biopharmaceutical company reported ($1.15) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.01. View Catalyst Biosciences' Earnings History.
When is Catalyst Biosciences' next earnings date?
What price target have analysts set for CBIO?
3 brokerages have issued 1-year price targets for Catalyst Biosciences' shares. Their forecasts range from $24.00 to $25.00. On average, they anticipate Catalyst Biosciences' stock price to reach $24.33 in the next twelve months. This suggests a possible upside of 345.7% from the stock's current price. View Analyst Price Targets for Catalyst Biosciences.
What is the consensus analysts' recommendation for Catalyst Biosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Biosciences.
Has Catalyst Biosciences been receiving favorable news coverage?
News stories about CBIO stock have been trending very negative this week, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Catalyst Biosciences earned a news impact score of -3.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Catalyst Biosciences.
Are investors shorting Catalyst Biosciences?
Catalyst Biosciences saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 285,600 shares, a decline of 11.3% from the August 30th total of 322,000 shares. Based on an average trading volume of 134,500 shares, the short-interest ratio is currently 2.1 days. Currently, 2.6% of the shares of the company are short sold. View Catalyst Biosciences' Current Options Chain.
Who are some of Catalyst Biosciences' key competitors?
Some companies that are related to Catalyst Biosciences include resTORbio (TORC), Constellation Pharmaceuticals (CNST), Cyclerion Therapeutics (CYCN), Molecular Templates (MTEM), ProQR Therapeutics (PRQR), Forty Seven (FTSV), MannKind (MNKD), Stealth BioTherapeutics (MITO), ProMetic Life Sciences (PFSCF), Evofem Biosciences (EVFM), Assembly Biosciences (ASMB), Provention Bio (PRVB), Xenon Pharmaceuticals (XENE), Galectin Therapeutics (GALT) and Aeglea Bio Therapeutics (AGLE).
What other stocks do shareholders of Catalyst Biosciences own?
Who are Catalyst Biosciences' key executives?
Catalyst Biosciences' management team includes the folowing people:
- Dr. Nassim Usman, Pres, CEO & Director (Age 59)
- Mr. Fletcher Payne, Chief Financial Officer (Age 56)
- Dr. Howard Levy, Chief Medical Officer (Age 65)
- Dr. Charles S. Craik, Co-Founder & Chairman of Scientific Advisory Board
- Mr. Andrew Hetherington M.B.A., Sr. VP of Technical Operations
How do I buy shares of Catalyst Biosciences?
Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Catalyst Biosciences' stock price today?
One share of CBIO stock can currently be purchased for approximately $5.46.
How big of a company is Catalyst Biosciences?
Catalyst Biosciences has a market capitalization of $65.63 million and generates $10,000.00 in revenue each year. The biopharmaceutical company earns $-30,060,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Catalyst Biosciences employs 21 workers across the globe.View Additional Information About Catalyst Biosciences.
What is Catalyst Biosciences' official website?
How can I contact Catalyst Biosciences?
Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-871-0761 or via email at [email protected]
MarketBeat Community Rating for Catalyst Biosciences (NASDAQ CBIO)
MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe CBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
